BY THE OPTIMIST DAILY EDITORIAL TEAM
For decades, high clinical risk and chemotherapy arrived together as a package deal in early breast cancer. A trial presented at the American Society of Clinical Oncology meeting in Chicago on May 30, 2026, is pulling them apart.
The OPTIMA trial enrolled more than 4,400 patients across the United Kingdom, all with early-stage estrogen receptor-positive, HER2-negative breast cancer flagged as high clinical risk by conventional measures. The question was whether a genomic assay could identify which patients actually needed chemotherapy and which would do just as well without it. A whopping 68 percent of them, it turned out, did not.
What the test measures
The assay at the center of the trial is Veracyte’s Prosigna Breast Risk of Recurrence test. It runs on tumor tissue already removed, analyzing gene expression patterns to return a Risk of Recurrence score and a 10-year probability of distant recurrence. The purpose: distinguish patients whose tumors are likely to respond to chemotherapy from those for whom it would make no difference.
OPTIMA was a randomized non-inferiority trial. Patients whose Prosigna scores came in low were assigned to endocrine therapy alone. Their outcomes tracked closely with those of patients who went through full chemotherapy.
The weight of that finding
Chemotherapy for early breast cancer is not just tiring. Cardiac damage, neuropathy, heightened infection risk, and cognitive effects that persist for years. For patients who were going to have the same outcome anyway, all of those costs were paid for nothing.
The Prosigna test predates this trial. What OPTIMA adds is randomized data at scale, more than 4,400 participants, showing that test-directed treatment holds up for a population previously assumed to need the full regimen.
The number that matters most is 68 percent. That is not a marginal slice of patients. Breast cancer is diagnosed in the hundreds of thousands annually in the US alone. If clinical practice shifts in response to this trial, a genomic test taken at diagnosis could tell a large share of those patients, upfront, that they do not need chemotherapy at all.
The trial also drew a clear line. The 32 percent whose scores pointed to higher recurrence risk still needed it. The test is a sorting mechanism. It does not say chemotherapy is avoidable; it says that, for more than two-thirds of the patients assessed, it was never necessary.
Did this solution stand out? Share it with a friend or support our mission by becoming an Emissary.
